NASDAQ: TLISTalis Biomedical Corp Stock
$9.00+0.10 (+1.12%)
Updated Apr 22, 2024
TLIS Price
$9.00
Fair Value Price
N/A
Market Cap
$285.17M
52 Week Low
$4.35
52 Week High
$9.32
P/E
-0.26x
P/B
4.13x
P/S
6.35x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.13M
Earnings
-$62.01M
Gross Margin
98.1%
Operating Margin
-2,905.67%
Profit Margin
-2,905.7%
Debt to Equity
0.37
Operating Cash Flow
-$53M
Beta
0.78
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
TLIS Overview
Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19. In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TLIS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TLIS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TLIS is poor value based on its book value relative to its share price (4.13x), compared to the US Medical Devices industry average (3.65x)
P/B vs Industry Valuation
TLIS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more TLIS due diligence checks available for Premium users.
Be the first to know about important TLIS news, forecast changes, insider trades & much more!
TLIS News
Valuation
TLIS fair value
Fair Value of TLIS stock based on Discounted Cash Flow (DCF)
Price
$9.00
Fair Value
$12.04
Undervalued by
25.26%
TLIS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TLIS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.26x
Industry
29.12x
Market
41x
TLIS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.13x
Industry
3.65x
TLIS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TLIS's financial health
Profit margin
Revenue
$195.0k
Net Income
-$13.5M
Profit Margin
-6,902.6%
TLIS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
TLIS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$94.7M
Liabilities
$25.6M
Debt to equity
0.37
TLIS's short-term assets ($77.68M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TLIS's short-term assets ($77.68M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TLIS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TLIS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$11.4M
Investing
$93.0k
Financing
$0.0
TLIS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TLIS vs Medical Device Stocks
Talis Biomedical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.